722 Type 2 helper T-cell (Th2) effects of crisaborole versus 3 topical corticosteroids (TCSs) with a range of potencies: An ex vivo human skin model study

The Th2 pathway plays a central role in the pathophysiology of atopic dermatitis (AD). Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate AD. An ex vivo human skin model with Th2 cytokine and T-cell stimulation was used to compare the T-cell and Th2 cytokine activation effects of crisaborole with TCSs of varying potencies (hydrocortisone cream, 1% [lowest], hydrocortisone butyrate cream, 0.1% [lower-medium], and betamethasone valerate cream, 0.1% [medium]).

Source: Journal of Investigative Dermatology - April 19, 2019 Category: Dermatology Authors: K. Nocka, W.C. Ports, B. Vlahos, C. Zang, G. Berstein, S.R. Feldman, M. Brown, A.V. Caserta, J.E. Neil Tags: Pharmacology and Drug Development Source Type: research